Evidence reviews – March 2019
The following documents contain the evidence that was used to develop the recommendations:
- Effectiveness of non-ultrasound-guided TBNA, EBUS-TBNA or EUS-FNA for people with a probability of mediastinal malignancy
- Clinical and cost-effectiveness of routine MRI or CT of the brain in the management of people with lung cancer prior to therapy with curative intent
- Clinical and cost effectiveness of treatment regimen for the treatment of operable Stage IIIA-N2 NSCLC
- Clinical and cost effectiveness of different radiotherapy regimens with curative intent for NSCLC
- Development of a systemic anti-cancer therapy algorithm
- Most clinically and cost-effective regimen of chemoradiotherapy for people with limited-stage SCLC
- Clinical and cost-effectiveness of first use of thoracic radiotherapy for people with extensive-stage SCLC who have had first-line treatment with systemic anti-cancer therapies
- Clinical and cost-effectiveness of prophylactic cranial irradiation to prevent brain metastases in people with extensive SCLC
This page was last updated: